
    
      A randomized, double-blind, active controlled, multicenter, parallel treatment, 3x3 dose
      level crossover study evaluating the dose response of levalbuterol in pediatric subjects
      between the ages of 6 and 11, inclusive with exercise induced bronchoconstriction. This study
      was previously posted by Sepracor Inc. In October 2009, Sepracor Inc. was acquired by
      Dainippon Sumitomo Pharma., and in October 2010, Sepracor Inc's name was changed to Sunovion
      Pharmaceuticals Inc.
    
  